Monoclonal antibody T101-Y-90 conjugate

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMonoclonal antibody T101-Y-90 conjugate

Drug Alias Name90Y-T101

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionIonising radiation emittersT-cell surface glycoprotein CD5 inhibitorsImmunosuppressants

TargetsT-cell surface glycoprotein CD5

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesHybritech Incorporated

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesHybritech Incorporated +[2]

Active IndicationsN/A

Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeN/A